In a new guidance statement, the American Diabetes Association advises against the use of unapproved products, warning of ...

Randomised controlled trials and real word evidence have consistently shown that GLP-1 receptor agonists are effective and ...

The darlings of the weight loss and diabetes spaces, GLP-1 receptor agonists have shown promise against Alzheimer’s in recent studies—with Phase III results expected next year from Novo Nordisk.

The EMA approved a kidney disease–related label expansion for the blockbuster GLP-1 drug after a study showed reduced risk of ...

This integration further streamlines access to the only approved dual GIP and GLP-1 receptor agonist without patients ever ...

Adults taking Zepbound lost 47% more weight on average than those taking Wegovy, according to clinical trial data from ...

One particular healthcare stock has shown its ability to soar on good news -- and it's had plenty of it. This year the ...

Those treated with tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonist, lost on ...

Weight loss drug fill rates by state, per GoodRx: Alaska — 2.57% Oklahoma — 2.17% Texas — 2.03% Alabama — 1.98% New Jersey — 1.85% Connecticut — 1.82% North Carolina — 1.77% North Dakota — 1.70% ...

W ith more people taking the weight-loss drugs Wegovy and Zepbound, one question inevitably arises: which one is more ...

People are reporting that their weight-loss medication helps them steer clear of drugs and alcohol. Studies are promising, ...

They’ve been heralded as the magic drugs that treat obesity when diet and exercise have failed. But Ozempic and Wegovy – and ...